Japan Pharmaceuticals and Healthcare Report Q2 208

Publication Date	April 2008
Publisher	Business Monitor
Product Type	Report
Pages	86
ISBN Number	not applicable
Product Code	BMI01681

Price

£425.00
approximately: $835 | €540

PDF immediate delivery

Order above formats by FAX

Summary

Japan's pharmaceutical market is currently valued at US$74.4bn and is easily the most mature in the Asia Pacific region. Top-line sales stagnated for the first time in 2006 and this scenario is likely to be repeated in 2007. However, this is a temporary trend as the country's vast ageing population will cause the market to expand once again. By 2012, we expect the value of market to reach US$82.0bn.

The country's generics sector is one of the most promising in BMI's coverage universe. In an effort to control ballooning healthcare costs, the ministry of health plans to raise the volumes share of generics within the total prescription market to at least 30% by 2012. The current value of the sector is US$5.5bn, which equates to 7.3% of total medicines sales. Changes to prescribing procedures and the influx of foreign firms with low-cost goods will provide a stimulus to the generic drug sector.

It has emerged that the debilitating and sometime deadly viral condition hepatitis C is grossly underdiagnosed in Japan. Spurred on by a tainted blood scandal, the government is looking to increase awareness of the disease, which is estimated to affect 1.4% of the population, or 1.75mn people. BMI believes that this campaign will provide a boost for manufacturers of testing kits and pharmaceutical companies that sell hepatitis C therapeutics, such as Switzerland's Roche and US firm Schering-Plough.

For fiscal-year 2008, the budget for the Ministry of Health, Labour and Welfare (MHLW) was been increased by 3.0% to JPY222bn (US$221bn). This compares favourably to overall economic growth in 2007, which was estimated to be 2.6% by BMI's Country Risk team. Within the MHLW's spending plan, emphasis has been placed on cancer prevention, medical research and development (R&D), hepatitis countermeasures, and stem cell research. Worryingly for drugmakers, funding for accelerated access to pharmaceuticals has been cut.

During Q108, Novartis became the latest multinational to scale back its research operations in Japan, with the planned closure of a facility in Tsukuba near Tokyo by the end of 2008. In recent years, numerous international drugmakers - Pfizer, Schering AG and GlaxoSmithKline (GSK) - have reduced their R&D footprint in Japan.

Content

Executive Summary
Japan Pharmaceuticals And Healthcare Industry SWOT
Japan Political SWOT
Japan Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Asia Pacific Pharmaceutical Business Environment Rankings, Q208
Limits Of Potential Returns
Risks To Realisation Of Returns
Japan - Market Summa10
Regulatory Regime
Case Study: Wyeth's Prevnar and Japanese Drug Lag
Recent Regulatory Developments
Medical Device Regulations
Intellectual Property Developments
Pricing And Reimbursement System
- Table: Reimbursement Categories And Rates
Recent Pricing And Reimbursement Developments
Other Regulatory Issues
- Table: Concerns Of Pharmaceutical Associations
Industry Trends And Developments
Epidemiology
- Table: Mortality By Cause In Japan
Healthcare Sector
Healthcare Sector Finance Issues
Healthcare Reforms
International Collaboration
International Reaction
Domestic Company Activity
Foreign Generic Sector
- Table: Timeline: Indian Manufacturers In Japan, 2005-2007
Multinational Sector Developments
Research And Development
Industry Forecast Sce31
Overall Market Forecast
- Table: Japanese Ethical Market - Leading Therapeutic Classes, FY05/06
- Table: Japan's Drug Market Indicators
Key Growth Factors - Industry
- Table: Japan's Healthcare Expenditure Indicators
Macroeconomic Forecast Scenario
- Table: Japan - Macroeconomic Forecasts
Prescription Market Forecast
- Table: Prescription Drug Market Indicators (US$mn unless otherwise stated)
OTC Market Forecast
- Table: OTC Market Indicators (US$mn unless otherwise stated)
Generics Market Forecast
- Table: Generics Market Trends
Patented Medicines Market Forecast
- Table: Patented Medicines Market Indicators
Export/Import Forecasts
- Table: Export/Import Trends (US$mn)
Other Healthcare Data And Forecasts
- Table: Socio-Demographic Indicators
Key Risks To BMI's Forecast Scenario
Competitive Landscape
- Table: Japanese Ethical Market - Sales Value (FY2006)
Company Profiles
Leading Foreign Manufacturers
Pfizer
Sanofi-Aventis
Merck & Co (Banyu)
Novartis
GlaxoSmithKline (GSK)
AstraZeneca
Indigenous Manufacturers
Takeda
Astellas
Eisai
Daiichi-Sankyo
Sawai Pharmaceutical
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
Weighting
- Table: Weighting Of Components
Sources